Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 134 results for atrial fibrillation

  1. The impact of atrial fibrillation on the natriuretic peptide threshold for diagnosing heart failure:- What is the optimal NT-proBNP threshold for the diagnosis of heart failure in people with atrial fibrillation?

    Recommendation ID NG106/3 Question The impact of atrial fibrillation on the natriuretic peptide threshold for diagnosing heart failure:-...

    Research recommendation
    Published
    17 December 2018

  2. The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices in primary care for people with signs or symptoms of atrial fibrillation, and an irregular pulse, increases the number of people with atrial fibrillation (including paroxysmal) detected,  ompared with current practice (that is, a 12‑lead ECG done later). The committee considered the feasibility of collecting data to see if using the lead‑I ECG devices increased the detection of atrial fibrillation that would be missed if only 12‑lead ECGs done later were available. It noted that even if a lead‑I ECG is used and atrial fibrillation is detected, a subsequent 12‑lead ECG would still be done to check for structural cardiac abnormalities and inform further management decisions. The committee concluded that practices using lead‑I ECG devices could determine the number of additional cases of atrial fibrillation detected by the devices. This can be done by identifying people with a confirmed positive lead‑I ECG for atrial fibrillation who subsequently had a 12‑lead ECG that was negative because the atrial fibrillation had stopped. The committee also considered that data collected on the time between the initial lead‑I ECG and the subsequent 12‑lead ECG would be useful.

    with signs or symptoms of atrial fibrillation, and an irregular pulse, increases the number of people with atrial...

    Research recommendation
    Published
    25 October 2019

  3. KODEX-EPD for cardiac imaging during ablation of arrhythmias (MIB260)

    NICE has developed a medtech innovation briefing (MIB) on KODEX-EPD for cardiac imaging during ablation of arrhythmias .

    Medtech innovation briefing
    Published
    11 May 2021

  4. Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)

    NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .

    Medtech innovation briefing
    Published
    14 September 2021

  5. Tests to diagnose persistent atrial fibrillation: What is the diagnostic accuracy of key index tests (such as the KardiaMobile heart monitor (AliveCor), MyDiagnostik, Microlife BP monitors, iPhone plethysmography and pulse palpation) compared with the gold standard of 12‑lead ECG in people with risk factors for or symptoms of atrial fibrillation?

    ID NG196/1 Question Tests to diagnose persistent atrial fibrillation: What is the diagnostic accuracy of key index tests (such as the...

    Research recommendation
    Published
    10 August 2021

  6. Stopping anticoagulation after ablation: What is the clinical and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation?

    and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation? Any explanatory...

    Research recommendation
    Published
    10 August 2021

  7. Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main drug classes used for rate control (beta‑blockers, calcium‑channel blockers and digoxin) in people aged 75 and over with atrial fibrillation in controlling symptoms, improving quality of life and reducing morbidity and mortality?

    Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main...

    Research recommendation
    Published
    10 August 2021

  8. NICE encourages clinicians to enter patients into research studies with the particular aims of guiding selection of patients and of defining the place of percutaneous balloon cryoablation in relation to other procedures for treating atrial fibrillation. Further research should define patient selection criteria clearly and should document adverse events and long-term control of atrial fibrillation.

    balloon cryoablation in relation to other procedures for treating atrial fibrillation. Further research should define patient selection...

    Research recommendation
    Published
    9 June 2015

  9. Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)

    This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.

    General practice indicators suitable for use in QOF
    Last updated
    4 November 2020

  10. NICE impact cardiovascular disease prevention

    Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention

  11. Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?

    from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?...

    Research recommendation
    Published
    10 August 2021

  12. Atrial fibrillation: pulse rhythm assessment in people at risk

    This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.

    Last updated
    27 August 2021

  13. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  14. Irreversible electroporation for treating liver metastases (IPG445)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG445

  15. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

    NICE guideline
    Published
    6 July 2016
    View recommendations

    Sections for NG49